[go: up one dir, main page]

DE60223674D1 - Vektoren zur gesteigerten expression von vegf zur behandlung von krankheiten - Google Patents

Vektoren zur gesteigerten expression von vegf zur behandlung von krankheiten

Info

Publication number
DE60223674D1
DE60223674D1 DE60223674T DE60223674T DE60223674D1 DE 60223674 D1 DE60223674 D1 DE 60223674D1 DE 60223674 T DE60223674 T DE 60223674T DE 60223674 T DE60223674 T DE 60223674T DE 60223674 D1 DE60223674 D1 DE 60223674D1
Authority
DE
Germany
Prior art keywords
vegf
vectors
diseases
treatment
increased expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60223674T
Other languages
English (en)
Inventor
Tjerk Johannes Visser
Folkert Feiko Roossien
Carola Jacoba Ubink-Bontekoe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fornix Biosciences NV
Original Assignee
Fornix Biosciences NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP01201944A external-priority patent/EP1262199A1/de
Application filed by Fornix Biosciences NV filed Critical Fornix Biosciences NV
Application granted granted Critical
Publication of DE60223674D1 publication Critical patent/DE60223674D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/60—Vectors comprising a special translation-regulating system from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60223674T 2001-05-23 2002-05-23 Vektoren zur gesteigerten expression von vegf zur behandlung von krankheiten Expired - Lifetime DE60223674D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01201944A EP1262199A1 (de) 2001-05-23 2001-05-23 Vektoren zur gesteigerten Expression von VEGF zur Behandlung von Krankheiten
US87310901A 2001-06-01 2001-06-01
PCT/NL2002/000326 WO2002095038A2 (en) 2001-05-23 2002-05-23 Vectors for enhanced expression of vegf for disease treatment

Publications (1)

Publication Number Publication Date
DE60223674D1 true DE60223674D1 (de) 2008-01-03

Family

ID=26076911

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60223674T Expired - Lifetime DE60223674D1 (de) 2001-05-23 2002-05-23 Vektoren zur gesteigerten expression von vegf zur behandlung von krankheiten

Country Status (5)

Country Link
EP (1) EP1395292B1 (de)
AU (1) AU2002309335A1 (de)
CA (1) CA2448132A1 (de)
DE (1) DE60223674D1 (de)
WO (1) WO2002095038A2 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004070018A2 (en) * 2003-02-04 2004-08-19 Ludwig Institute For Cancer Research Vegf-b and pdgf modulation of stem cells

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69229390T2 (de) * 1991-08-26 1999-11-11 Immuno Ag, Wien Direkt molekuläre Klonierung eines modifizierten Genoms eines Chordopocken-Virus
US5919652A (en) * 1994-11-09 1999-07-06 The Regents Of The University Of California Nucleic acid molecules comprising the prostate specific antigen (PSA) promoter and uses thereof
US5830879A (en) * 1995-10-02 1998-11-03 St. Elizabeth's Medical Center Of Boston, Inc. Treatment of vascular injury using vascular endothelial growth factor
CA2323112A1 (en) * 1998-03-16 1999-09-23 Introgen Therapeutics, Inc. Multigene vectors
US6706491B1 (en) * 1999-04-09 2004-03-16 The Board Of Trustees Of The University Of Illinois Reagents and methods for identifying and modulating expression of genes regulated by p21

Also Published As

Publication number Publication date
EP1395292B1 (de) 2007-11-21
EP1395292A2 (de) 2004-03-10
WO2002095038A2 (en) 2002-11-28
WO2002095038A3 (en) 2003-10-30
AU2002309335A1 (en) 2002-12-03
CA2448132A1 (en) 2002-11-28

Similar Documents

Publication Publication Date Title
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
DE602004028763D1 (de) Te zur behandlung von virenerkrankungen
ATE417602T1 (de) Mittel zur behandlung von erkrankungen der speiseröhre
EP1622633A4 (de) Behandlung von t-zell-vermittelten krankheiten
DE60204466D1 (de) Integrinhemmer zur behandlung von augenkrankheiten
ATE417037T1 (de) Diarylharnstoffderivate, die sich zur behandlung von proteinkinaseabhängigen krankheiten eignen
DE60218493D1 (de) Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten
DE602004020072D1 (de) 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen
NO20041882L (no) Fremgangsmater for behandling av okulare neovaskulaere sykdommer.
ATE472325T1 (de) Intrakorporale medikamente zur photodynamischen behandlung von erkrankungen
ATE358669T1 (de) Pyrazolderivate zur behandlung von hiv
ATE512163T1 (de) Verabreichung von mitteln zur behandlung von entzündungen
DE60234760D1 (de) Phenylindole zur behandlung von hiv
DE60123238D1 (de) Zusammensetzungen zur behandlung von autoimmunkrankheiten
ATE384522T1 (de) Medikamente zur chemotherapeutischen behandlung von erkrankungen
DE60239558D1 (de) Kombinationen für die behandlung von immun-entzündlichen erkrankungen
DE60136477D1 (de) Retinoide zur behandlung von emphysem
ATE443704T1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
DE50013843D1 (de) Arzneimittel zur behandlung von darmerkrankungen
DE60238765D1 (de) Carbamatverbindungen zur behandlung von schmerz
DE50105735D1 (de) Chlorzoxazon zur behandlung von psoriasis
DE60016047D1 (de) Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2-abhängiger krankheiten
DE50205466D1 (de) Substituierte 2,5-diamidoindole als ece-inhibitoren zur behandlung von kardiovaskulären erkrankungen
DE60103685D1 (de) Behandlung von Poriomania
ATE330938T1 (de) Disulfid-derivate verwendbar zur behandlung von allergischen erkrankungen

Legal Events

Date Code Title Description
8332 No legal effect for de